CDXS Stock Overview
Codexis, Inc. discovers, develops, and sells enzymes and other proteins.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Codexis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.44 |
| 52 Week High | US$22.22 |
| 52 Week Low | US$4.21 |
| Beta | 1.48 |
| 1 Month Change | 38.20% |
| 3 Month Change | 12.78% |
| 1 Year Change | -67.51% |
| 3 Year Change | -60.45% |
| 5 Year Change | -21.94% |
| Change since IPO | -51.43% |
Recent News & Updates
Recent updates
Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?
Nov 05
Codexis appoints Kevin Norrett as chief operating officer
Oct 03We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth
Aug 23Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%
Jul 28Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead
Jul 27Codexis gets new executive chief
Jul 18Are Investors Undervaluing Codexis, Inc. (NASDAQ:CDXS) By 35%?
Jul 06Why Codexis, Inc. (NASDAQ:CDXS) Could Be Worth Watching
May 10Codexis: A Company Rooting Itself In A Blossoming Market
Apr 18We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Apr 09Does This Valuation Of Codexis, Inc. (NASDAQ:CDXS) Imply Investors Are Overpaying?
Mar 14Codexis (NASDAQ:CDXS) Is In A Strong Position To Grow Its Business
Dec 24Codexis, Inc. (NASDAQ:CDXS) Shares Could Be 39% Below Their Intrinsic Value Estimate
Nov 07Upgrade: Analysts Just Made A Notable Increase To Their Codexis, Inc. (NASDAQ:CDXS) Forecasts
Aug 08Companies Like Codexis (NASDAQ:CDXS) Are In A Position To Invest In Growth
Aug 03Codexis price target raised at H.C. Wainwright citing new purchase order
Jun 18Here's Why We Think Codexis, Inc.'s (NASDAQ:CDXS) CEO Compensation Looks Fair for the time being
Jun 09Is There Now An Opportunity In Codexis, Inc. (NASDAQ:CDXS)?
May 11Codexis EPS beats by $0.07, beats on revenue
May 06Companies Like Codexis (NASDAQ:CDXS) Are In A Position To Invest In Growth
Apr 15Codexis (NASDAQ:CDXS) Shareholders Have Enjoyed A Whopping 578% Share Price Gain
Mar 20Estimating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)
Feb 22What Is Codexis, Inc.'s (NASDAQ:CDXS) Share Price Doing?
Jan 27
Shareholder Returns
| CDXS | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -2.6% | -0.03% | 1.7% |
| 1Y | -67.5% | -15.2% | -12.5% |
Return vs Industry: CDXS underperformed the US Life Sciences industry which returned -15.2% over the past year.
Return vs Market: CDXS underperformed the US Market which returned -12.5% over the past year.
Price Volatility
| CDXS volatility | |
|---|---|
| CDXS Average Weekly Movement | 12.1% |
| Life Sciences Industry Average Movement | 11.7% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CDXS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: CDXS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 261 | Stephen Dilly | https://www.codexis.com |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.
Codexis, Inc. Fundamentals Summary
| CDXS fundamental statistics | |
|---|---|
| Market Cap | US$403.98m |
| Earnings (TTM) | -US$31.18m |
| Revenue (TTM) | US$132.72m |
3.2x
P/S Ratio-13.6x
P/E RatioIs CDXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDXS income statement (TTM) | |
|---|---|
| Revenue | US$132.72m |
| Cost of Revenue | US$113.15m |
| Gross Profit | US$19.57m |
| Other Expenses | US$50.74m |
| Earnings | -US$31.18m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 14.74% |
| Net Profit Margin | -23.49% |
| Debt/Equity Ratio | 0% |
How did CDXS perform over the long term?
See historical performance and comparison